Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival
Open Access
- 1 April 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Research and Reports in Urology
- Vol. ume 12, 157-165
- https://doi.org/10.2147/rru.s249417
Abstract
Background: Decreased expression of thrombomodulin (TM) in bladder cancer tissue has been shown to be associated with cell proliferation, increased malignancy and a poor prognosis. The aim of this study was to investigate the immunoexpression of TM in bladder tissue cores by immunohistochemistry (IHC) and the relationship between TM score and patient survival for the following pathologies: transitional cell papillary carcinoma (TCPC), transitional cell carcinoma (non-papillary) (TCC), squamous cell carcinoma (SCC), adenocarcinoma, and sarcoma. TM immunoexpression was also evaluated in normal adjacent bladder tissue cores. Methods: TM immunoexpression was assessed in n=185 formalin-fixed paraffin-embedded (FFPE) bladder tissue cores from n=98 patients by IHC. Tissue cores included TCPC (n=29), TCC (n=85), SCC (n=21), adenocarcinoma (n=12), sarcoma (n=4), and normal tissue cores (n=34). Results: TM immunoexpression scores are stronger in TCPC, TCC and SCC bladder cancer tissue cores with respect to adenocarcinoma and sarcoma (mean TM immunoexpression scores: 3.04, 2.57, 2.55, 1.55 and 1.19, respectively) (Kruskal–Wallis p< 0.001). TM immunoexpression scores significantly decreased in bladder cancer tissue cores across both stage (p< 0.001) and grade (p< 0.001) (Kruskal–Wallis). Survival data were available for n=45 bladder cancer patients (mean follow-up of 34 months). Applying a TM immunoexpression cut-off score of 3.0 demonstrated that patients with bladder cancer who had a TM immunoexpression score < 3.0 had lower survival rates (median survival 23.5 months). In contrast, patients with TM immunoexpression scores ≥ 3.0 had longer survival rates (median survival 40 months) (log-rank; p=0.045). Conclusion: TM immunoexpression in bladder cancer tissue may be a clinically relevant predictor of tumor progression and survival. Low expression of TM in bladder cancer biopsies or in recurrent bladder cancer may be indicative of a poor prognosis. TM immunoexpression could be used to guide clinical decision making.This publication has 27 references indexed in Scilit:
- Thrombomodulin mediates the migration of cervical cancer cells through the regulation of epithelial–mesenchymal transition biomarkersTumor Biology, 2013
- Best practice in the treatment of nonmuscle invasive bladder cancerTherapeutic Advances in Urology, 2011
- The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuriaCancer, 2011
- The excessive cost of early stage bladder cancer careCancer, 2010
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- Economic aspects of bladder cancer: what are the benefits and costs?World Journal of Urology, 2009
- The present and future burden of urinary bladder cancer in the worldWorld Journal of Urology, 2009
- Thrombomodulin expression in colorectal carcinoma is protective and correlates with survivalBritish Journal of Cancer, 2006
- A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.Journal of Clinical Pathology, 1997
- A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis.The Journal of cell biology, 1991